Testing Settings of NovaResp's cMAP® Software During Home PAP Therapy
Key facts
- Where
- Halifax, CanadaSee the site
Where in Canada
- NovaResp Technologies Inc.Halifax, CanadaContact: Megan Neil, BScNNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- NovaResp Technologies Inc
- Trial code
- NCT07898254
- Record updated
- 27 October 2026
- Original description
The goal of this clinical trial is to identify which settings of proactive therapy work best in OSA patients who regularly adhere to PAP therapy at home. The main question(s) it aims to answer are:Read full original descriptionShow less
Experimental Evaluation of cMAP® Therapy Parameters Delivered Through Commercial Positive Airway Pressure (PAP) Devices in Adults Using PAP Therapy at Home
The goal of this clinical trial is to identify which settings of proactive therapy work best in OSA patients who regularly adhere to PAP therapy at home. The main question(s) it aims to answer are:
* To assess how different settings of proactive therapy affect therapy effectiveness * To assess whether proactive therapy works similarly across different PAP devices Participants will undergo conventional APAP therapy and two modes of proactive therapy on two different PAP devices.
Nights in which conventional APAP was used and nights in which proactive therapy was used to see which settings treated patients most effectively.
Inclusion: Must have a diagnosis of OSA (AHI ≥ 5), with central events less than 50% of all events; Must have used a PAP device for more than 4 months; Must use PAP therapy for more than 4 hours per night; Must have a median therapy pressure between 6 and 20 cmH₂O; Must be able to operate the study devices at home and wear the sleep diagnostic ring each night; be able to understand English and give written informed consent.
Exclusion: Subjects actively using bi-level PAP or require oxygen therapy; Excess leak (greater than 24 L/min) for more than 10% of the time on therapy; Significant or unstable cardiovascular, respiratory, neurological, or psychiatric disease; Any condition that, in the opinion of the clinician, makes unsupervised home use unsafe; Neuromuscular disease, hypoglossal-nerve palsy, severe restrictive or obstructive pulmonary disease, moderate-to-severe pulmonary arterial hypertension, severe valvular heart disease, New York Heart Association class III or IV heart failure, recent myocardial infarction or severe cardiac arrhythmias, or persistent uncontrolled hypertension despite medication use; Known treatment-emergent or complex central sleep apnea; Pregnancy, planning to become pregnant, or breastfeeding.